Lantheus Holdings (LNTH) Change in Accured Expenses (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Change in Accured Expenses came in at $23.0 million in Q1 2026, up 591.23% year-on-year from $3.3 million in Q1 2025, and up 15.89% on a QoQ basis from $19.8 million in Q4 2025.
Lantheus Holdings (LNTH) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Change in Accured Expenses data on file, last reported at $23.0 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 591.23% year-over-year to $23.0 million in Q1 2026; TTM through Mar 2026 was $10.6 million, a 3092.66% increase from a year earlier, with the FY2025 full-year figure at -$9.1 million, down 119.42% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $23.0 million, up from $19.8 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for LNTH reached as high as $50.4 million in Q1 2024 and fell as low as -$123.8 million in Q2 2023.
- Historically, Change in Accured Expenses has averaged $2.5 million across 5 years, with a median of $8.1 million in 2023.
- Across the five-year window, Change in Accured Expenses soared 1237.99% in 2023 and sank 1553.76% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $33.2 million in 2022, then slumped by 75.66% to $8.1 million in 2023, then soared by 249.39% to $28.2 million in 2024, then decreased by 29.7% to $19.8 million in 2025, then grew by 15.89% to $23.0 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $23.0 million in Q1 2026, $19.8 million in Q4 2025, and -$26.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 23.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.00 Mn |
| Mar 31, 2026 | 23.00 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | -26.31 Mn |
| Sep 30, 2025 | -26.31 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 28.24 Mn |
| Dec 31, 2024 | 28.24 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | -33.73 Mn |
| Jun 30, 2024 | -33.73 Mn |
| Mar 31, 2024 | 50.45 Mn |
| Mar 31, 2024 | 50.45 Mn |
| Dec 31, 2023 | 8.08 Mn |
| Dec 31, 2023 | 8.08 Mn |